Drug intelligence / Profile preview

SAN-61

Development stage: Preclinical
Lead developer: DiaMedica Therapeutics
Modality: Recombinant Proteins and Enzymes

Overview

**SAN-61** is a repurposed recombinant protein product initially developed by Sanomune, a subsidiary of DiaMedica Therapeutics, Inc., for the treatment of Alzheimer's disease. It functions as an inhibitor of amyloid precursor protein (APP) and tau protein, key pathological targets in Alzheimer's disease implicated in amyloid plaque formation and neurofibrillary tangle accumulation, respectively. The drug represents an early-stage therapeutic approach targeting core Alzheimer's pathology, though detailed clinical data and current development progress remain limited.

Targets

Aβ (Amyloid-beta peptides and aggregates)MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on SAN-61.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAN-61.

Explore the full profile